Nasdaq:US$13.30 (+0.08) | HKEX:HK$20.50 (-0.70) | AIM:£2.12 (-0.07)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 6 Apr 2013

AACR 2013: Synergistic effect of c-Met inhibitor savolitinib in combination with EGFR inhibitor Gefitinib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification